Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $565.5 million.

  • Roivant Sciences' Non-Current Assets rose 3200.48% to $565.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 695.01%. This contributed to the annual value of $202000.0 for FY2025, which is 9859.9% down from last year.
  • As of Q4 2025, Roivant Sciences' Non-Current Assets stood at $565.5 million, which was up 3200.48% from $551.0 million recorded in Q3 2025.
  • Over the past 5 years, Roivant Sciences' Non-Current Assets peaked at $591.0 million during Q1 2023, and registered a low of $202000.0 during Q1 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $503.3 million (2022), whereas its average is $448.9 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 4126.74% in 2022, then crashed by 9859.9% in 2025.
  • Roivant Sciences' Non-Current Assets (Quarter) stood at $511.8 million in 2021, then grew by 8.77% to $556.7 million in 2022, then decreased by 9.12% to $505.9 million in 2023, then decreased by 15.33% to $428.4 million in 2024, then skyrocketed by 32.0% to $565.5 million in 2025.
  • Its last three reported values are $565.5 million in Q4 2025, $551.0 million for Q3 2025, and $416.9 million during Q2 2025.